Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBITDA (2021 - 2026)

bioAffinity Technologies has reported EBITDA over the past 5 years, most recently at -$3.6 million for Q1 2026.

  • Quarterly EBITDA fell 39.06% to -$3.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$11.4 million through Mar 2026, down 20.52% year-over-year, with the annual reading at -$10.4 million for FY2025, 18.33% down from the prior year.
  • EBITDA was -$3.6 million for Q1 2026 at bioAffinity Technologies, down from -$3.1 million in the prior quarter.
  • Over five years, EBITDA peaked at -$684119.0 in Q2 2022 and troughed at -$3.6 million in Q1 2026.
  • The 5-year median for EBITDA is -$2.0 million (2024), against an average of -$2.0 million.
  • Year-over-year, EBITDA crashed 156.88% in 2023 and then increased 14.05% in 2024.
  • A 5-year view of EBITDA shows it stood at -$1.6 million in 2022, then plummeted by 34.62% to -$2.2 million in 2023, then crashed by 33.44% to -$2.9 million in 2024, then fell by 6.74% to -$3.1 million in 2025, then fell by 15.91% to -$3.6 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's EBITDA are -$3.6 million (Q1 2026), -$3.1 million (Q4 2025), and -$2.2 million (Q3 2025).